Sermorelin · dosing reference
A 29-amino acid GHRH fragment (GHRH 1-29 amide). Formerly FDA-approved as Geref for diagnostic pituitary evaluation and idiopathic growth hormone deficiency.
Intervention parameters reported in individual published human studies. Each study stays separate; parameters are never aggregated across studies.
What people report discussing or doing in forums, on Reddit and in videos. Included only to show demand and reported practice — never as clinical evidence.
Typically discussed around 200–500 mcg (0.2–0.5 mg) administered subcutaneously once daily before sleep.
Community reports describe what people say they are doing. They are not equivalent to clinical evidence, and discussion volume says nothing about whether a practice is safe, effective or even real.
People search for dose information before they search for anything else in this sector. Where discussion is widespread, pretending it does not exist helps nobody. Therapept reports the discussion — its rough shape, how common it is, and where it happens — while keeping it visibly separate from every other kind of source. Community reports describe what people say they are doing. They are not equivalent to clinical evidence.
Last reviewed 22 September 2026 · Compiled by Therapept Editorial · How these records are built
